We discovered transcriptional effector domains in 600 human proteins and shed new light on the evolution of major transcription factor families, like KRAB and Hox, while also engineering improved activator and repressor domains for synthetic biology.
We identified novel recombinases from bacteriophages that can integrate large DNA sequences into the human genome. Previously, we used AAV vectors to deliver antibody genes as a way to prevent RSV infection.
Genetic and epigenetic editing
We built and used CRISPR tools to functionally investigate the non-coding genome. We also developed new biochemical, cellular, and computational approaches to measure, model, and mitigate CRISPR off-target effects to make safer therapies.